Neuroblastoma Surface Targets

The idea: A protein is a good immunotherapy target (CAR-T, ADC, antibody) if it sits on the cell surface, is abundant on the tumor, and is absent / low in normal tissues (so the therapy doesn't attack healthy organs).

How it was measured: Plasma-membrane-enriched mass spectrometry on 9 neuroblastoma cell lines and 12 xenograft models directly detected proteins on the cell surface — this is experimental, not predicted.

Reading the safety column: Tumor specificity = the number of 22 normal tissues where the gene is expressed within 4× of the tumor (i.e. not specific there). Lower = more tumor-specific = safer. Sort by the target score (surface abundance × specificity) to rank candidates, then open any protein to see its full normal-tissue safety profile.